Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28203660 | 0.86 | CYP4F2 (0.49) | CYP4A11CYP4F2ALDH1A1MAPTHPGD | |
| SCHEMBL29943277 | 0.86 | ALDH1A1 (0.53) | CYP4A11CYP4F2ALDH1A1KDM4EGAA | |
| SCHEMBL1022658 | 0.86 | ALDH1A1 (0.53) | CYP4A11CYP4F2ALDH1A1KDM4EGAA | |
| SCHEMBL5502090 | 0.86 | ALDH1A1 (0.49) | CYP4A11ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL7410301 | 0.85 | CYP4F2 (0.68) | CYP4A11CYP4F2ALDH1A1KDM4EGAA | |
| SCHEMBL498143 | 0.84 | CA12 (0.52) | CYP4A11CYP4F2ALDH1A1KDM4EGAA | |
| SCHEMBL5954327 | 0.84 | CYP4A11 (0.46) | CYP4A11CYP4F2ALDH1A1KDM4EGAA | |
| SCHEMBL4686032 | 0.83 | ALDH1A1 (0.46) | CYP4A11CYP4F2ALDH1A1KDM4EGAA | |
| SCHEMBL13162022 | 0.83 | CA12 (0.47) | CYP4A11ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL3174714 | 0.83 | LOXL2 (0.61) | CYP4A11ALDH1A1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114414684-A | Method for detecting flurarana intermediate and isomer thereof | 丽珠集团新北江制药股份有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-109134295-A | Amerantrone derivative and its preparation method and application | 山东大学 | 2019-01-04 | — | — | CN | claimed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| CN-117736182-A | MetTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20230416460-A1 | COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED PRODUCT, AND LAMINATED SUBSTRATE | TDK CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| CN-116490355-A | Compound, resin composition, resin sheet, resin cured product, and laminated substrate | TDK株式会社 | 2023-07-25 | — | — | CN | disclosed |
| CN-114414684-B | Florarana intermediate and detection method of isomer thereof | 丽珠集团新北江制药股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2022263829-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-12-22 | — | — | WO | disclosed |
| CN-114414684-A | Method for detecting flurarana intermediate and isomer thereof | 丽珠集团新北江制药股份有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-4708441-A | LIQUID CRYSTALS | HOFFMAN-LA ROCHE INC. (US) | 1987-11-24 | — | — | US | disclosed |
| US-4704005-A | LIQUID CRYSTALS | HOFFMANN-LA ROCHE INC. (US) | 1987-11-03 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| US-4613208-A | ELECTROOPTICS; ULTRAVIOLET RADIATION STABILITY; QUICK RESPONSE | HOFFMANN-LA ROCHE INC. (US) | 1986-09-23 | — | — | US | disclosed |
| US-4595521-A | In liquid crystalline carrier | HOFFMANN-LA ROCHE INC. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4550981-A | Liquid crystalline esters and mixtures | HOFFMANN-LA ROCHE INC. (US) | 1985-11-05 | — | — | US | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP4A11 3839/4885CYP4F2 2622/4885ALDH1A1 2407/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP4A11 3816/4885CYP4F2 2691/4885ALDH1A1 2371/4885 |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | POLI, POLR2E, POLR2H | CYP4A11 354/4885CYP4F2 803/4885ALDH1A1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.